Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.

Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19. Me...

Descripción completa

Detalles Bibliográficos
Autores: Ramos-Rincon, Jose-Manuel, López-Carmona, María-Dolores, Cobos-Palacios, Lidia, López-Sampalo, Almudena, Rubio-Rivas, Manuel, Martín-Escalante, María-Dolores, de-Cossio-Tejido, Santiago, Taboada-Martínez, María-Luisa, Muiño-Miguez, Antonio, Areses-Manrique, Maria, Martinez-Cilleros, Carmen, Tuñón-de-Almeida, Carlota, Abella-Vázquez, Lucy, Martínez-Gonzalez, Angel-Luís, Díez-García, Luis-Felipe, Ripper, Carlos-Jorge, Asensi, Víctor, Martinez-Pascual, Angeles, Guisado-Vasco, Pablo, Lumbreras-Bermejo, Carlos, Gómez-Huelgas, Ricardo, On Behalf Of The Semi-Covid-Network,
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/18688
Acceso en línea:http://hdl.handle.net/20.500.12105/18688
Access Level:acceso abierto
Palabra clave:COVID-19
SARS-CoV-2
Spain
Age ≥ 80
Mortality
Remdesivir
Descripción
Sumario:Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19. Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p < 0.001)). Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19.

Similares en LA Referencia